HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Double-blind cross-over study with org OD 14 and placebo in postmenopausal patients
Summary A double-blind cross-over study with Org OD 14 was done in 35 post-menopausal patients aged 48–69 years who had hot flushes and other associated symptoms . Patients were r and omly allocated to Org OD 14 or to placebo as first treatment . Each period of treatment lasted for 6 weeks and there were no intervals between treatments . Tablets containing 2.5 mg of Org OD 14 or placebo tablets of identical appearance were supplied . Patients took one Org OD 14 tablet or one placebo tablet per day . Data on the following variables were obtained and analyzed statistically : hot flushes , sweating , dizziness , palpitation , tiredness , headache , insomnia , irritability , breathlessness , backache , loss of libido , and mood . Assessment was daily in the case of hot flushes and weekly for the other variables . Org OD 14 was statistically significantly more effective in controlling hot flushes , sweating and headache and tended to be better than the placebo tablets for the other variables
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .